Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.

<h4>Objectives</h4>The application of susceptibility weighted imaging (SWI) in brain tumor imaging is mainly used to assess tumor-related "susceptibility based signals" (SBS). The origin of SBS in glioblastoma is still unknown, potentially representing calcifications or blood d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andreas Deistung, Ferdinand Schweser, Benedikt Wiestler, Mario Abello, Matthias Roethke, Felix Sahm, Wolfgang Wick, Armin Michael Nagel, Sabine Heiland, Heinz-Peter Schlemmer, Martin Bendszus, Jürgen Rainer Reichenbach, Alexander Radbruch
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d60784aa52954cdcacfc76c82248e183
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d60784aa52954cdcacfc76c82248e183
record_format	dspace
spelling	oai:doaj.org-article:d60784aa52954cdcacfc76c82248e1832021-11-18T07:52:31ZQuantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.1932-620310.1371/journal.pone.0057924https://doaj.org/article/d60784aa52954cdcacfc76c82248e1832013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23555565/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objectives</h4>The application of susceptibility weighted imaging (SWI) in brain tumor imaging is mainly used to assess tumor-related "susceptibility based signals" (SBS). The origin of SBS in glioblastoma is still unknown, potentially representing calcifications or blood depositions. Reliable differentiation between both entities may be important to evaluate treatment response and to identify glioblastoma with oligodendroglial components that are supposed to present calcifications. Since calcifications and blood deposits are difficult to differentiate using conventional MRI, we investigated whether a new post-processing approach, quantitative susceptibility mapping (QSM), is able to distinguish between both entities reliably.<h4>Materials and methods</h4>SWI, FLAIR, and T1-w images were acquired from 46 patients with glioblastoma (14 newly diagnosed, 24 treated with radiochemotherapy, 8 treated with radiochemotherapy and additional anti-angiogenic medication). Susceptibility maps were calculated from SWI data. All glioblastoma were evaluated for the appearance of hypointense or hyperintense correlates of SBS on the susceptibility maps.<h4>Results</h4>43 of 46 glioblastoma presented only hyperintense intratumoral SBS on susceptibility maps, indicating blood deposits. Additional hypointense correlates of tumor-related SBS on susceptibility maps, indicating calcification, were identified in 2 patients being treated with radiochemotherapy and in one patient being treated with additional anti-angiogenic medication. Histopathologic reports revealed an oligodendroglial component in one patient that presented calcifications on susceptibility maps.<h4>Conclusions</h4>QSM provides a quantitative, local MRI contrast, which reliably differentiates between blood deposits and calcifications. Thus, quantitative susceptibility mapping appears promising to identify rare variants of glioblastoma with oligodendroglial components non-invasively and may allow monitoring the role of calcification in the context of different therapy regimes.Andreas DeistungFerdinand SchweserBenedikt WiestlerMario AbelloMatthias RoethkeFelix SahmWolfgang WickArmin Michael NagelSabine HeilandHeinz-Peter SchlemmerMartin BendszusJürgen Rainer ReichenbachAlexander RadbruchPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e57924 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Andreas Deistung Ferdinand Schweser Benedikt Wiestler Mario Abello Matthias Roethke Felix Sahm Wolfgang Wick Armin Michael Nagel Sabine Heiland Heinz-Peter Schlemmer Martin Bendszus Jürgen Rainer Reichenbach Alexander Radbruch Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.
description	<h4>Objectives</h4>The application of susceptibility weighted imaging (SWI) in brain tumor imaging is mainly used to assess tumor-related "susceptibility based signals" (SBS). The origin of SBS in glioblastoma is still unknown, potentially representing calcifications or blood depositions. Reliable differentiation between both entities may be important to evaluate treatment response and to identify glioblastoma with oligodendroglial components that are supposed to present calcifications. Since calcifications and blood deposits are difficult to differentiate using conventional MRI, we investigated whether a new post-processing approach, quantitative susceptibility mapping (QSM), is able to distinguish between both entities reliably.<h4>Materials and methods</h4>SWI, FLAIR, and T1-w images were acquired from 46 patients with glioblastoma (14 newly diagnosed, 24 treated with radiochemotherapy, 8 treated with radiochemotherapy and additional anti-angiogenic medication). Susceptibility maps were calculated from SWI data. All glioblastoma were evaluated for the appearance of hypointense or hyperintense correlates of SBS on the susceptibility maps.<h4>Results</h4>43 of 46 glioblastoma presented only hyperintense intratumoral SBS on susceptibility maps, indicating blood deposits. Additional hypointense correlates of tumor-related SBS on susceptibility maps, indicating calcification, were identified in 2 patients being treated with radiochemotherapy and in one patient being treated with additional anti-angiogenic medication. Histopathologic reports revealed an oligodendroglial component in one patient that presented calcifications on susceptibility maps.<h4>Conclusions</h4>QSM provides a quantitative, local MRI contrast, which reliably differentiates between blood deposits and calcifications. Thus, quantitative susceptibility mapping appears promising to identify rare variants of glioblastoma with oligodendroglial components non-invasively and may allow monitoring the role of calcification in the context of different therapy regimes.
format	article
author	Andreas Deistung Ferdinand Schweser Benedikt Wiestler Mario Abello Matthias Roethke Felix Sahm Wolfgang Wick Armin Michael Nagel Sabine Heiland Heinz-Peter Schlemmer Martin Bendszus Jürgen Rainer Reichenbach Alexander Radbruch
author_facet	Andreas Deistung Ferdinand Schweser Benedikt Wiestler Mario Abello Matthias Roethke Felix Sahm Wolfgang Wick Armin Michael Nagel Sabine Heiland Heinz-Peter Schlemmer Martin Bendszus Jürgen Rainer Reichenbach Alexander Radbruch
author_sort	Andreas Deistung
title	Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.
title_short	Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.
title_full	Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.
title_fullStr	Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.
title_full_unstemmed	Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.
title_sort	quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/d60784aa52954cdcacfc76c82248e183
work_keys_str_mv	AT andreasdeistung quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT ferdinandschweser quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT benediktwiestler quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT marioabello quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT matthiasroethke quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT felixsahm quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT wolfgangwick quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT arminmichaelnagel quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT sabineheiland quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT heinzpeterschlemmer quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT martinbendszus quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT jurgenrainerreichenbach quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma AT alexanderradbruch quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
_version_	1718422881849835520

Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.

Ejemplares similares